UBS Group
TRIV

UBS Group’s TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK TRIV Stock Holding History

UBS Group’s Portfolio TRIV Stock Details TRIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,567
Closed -$77K – 8753
2015
Q4 		$77K Buy
11,567
+3,567
+45% +$23.7K ﹤0.01% 5432
2015
Q3 		$40K Buy
8,000
+54
+0.7% +$290 ﹤0.01% 6032
2015
Q2 		$43K Sell
7,946
-1,783
-18% -$12.6K ﹤0.01% 6137
2015
Q1 		$102K Buy
9,729
+7,596
+356% +$78.3K ﹤0.01% 5402
2014
Q4 		$27K Buy
+2,133
New +$29.1K ﹤0.01% 7256

UBS Group's TRIV Position: Q1 2016 in Review

UBS Group sold out of TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK (TRIV) in Q1 2016, closing a stake of 11,567 shares — an estimated $77K sold.

UBS Group first reported a position in TRIV in Q4 2014 and held it in 5 quarters. The position peaked at $102K in Q1 2015. 0 funds tracked by Wall St. Rank hold TRIV as of Q1 2016.

  • UBS Group reported no remaining TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • UBS Group sold 11,567 TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK shares in Q1 2016, an estimated $77K.
  • UBS Group first reported a position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK in Q4 2014 and held it in 5 quarters.
  • UBS Group's TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK position peaked at $102K in Q1 2015.
  • 0 funds tracked by Wall St. Rank held TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK as of Q1 2016.

Based on UBS Group's 13F filing for Q1 2016, filed 12 May 2016.